Accessioning and processing of multiple specimen types: fresh-in-formalin tissues, formalin-fixed paraffin-embedded (FFPE) blocks, unstained slides, stained slides, blood, bone marrow, or digital images.
GoPath's GeneticsNow® Series includes a collection of next-generation sequencing panels that detect germline variants associated with an increased risk for various hereditary cancers.
Our germline tests are clinical grade, with fast turnaround times and actionable results. We also have in-house certified genetic counselors to aid in interpretation of results and to provide guidance to patients.
Our targeted somatic next-generation sequencing panel, OncoTarget®500, integrates the robust bioinformatics of PGDx Elio Tissue Complete and provides physicians and researchers with comprehensive genomic insights for over 500
FDA-cleared for use in all solid tumors, OncoTarget®500 harnesses vast genomic data to identify personalized treatment options.
Whether a patient is in remission or currently undergoing treatment, the sooner cancer recurrence is discovered, the sooner the patient can receive appropriate treatments.
With OncoTracking™, signs of recurrence can be identified sooner than traditional screening tools. OncoTracking™ is a highly sensitive monitoring tool that utilizes liquid biopsy to screen for circulating tumor DNA (ctDNA), which is indicative of cancer recurrence and can be found before the recurrence is detectable on imaging.